Skip to Content


In the US, Bortezomib (bortezomib systemic) is a member of the drug class proteasome inhibitors and is used to treat Lymphoma, Mantle Cell Lymphoma and Multiple Myeloma.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Proteasome inhibitor

Chemical Names

{(1R)-3-metyl-1-[(2S)-3-phenyl-2-(pyrazin-2-carboxamido)propanamido]butyl}boronic acid (WHO)

Boronic acid, [(1R)-3-metyl-1-[[(2S)-1-oxo-3-phenyl-2[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- (USAN)

Foreign Names

  • Bortezomibum (Latin)
  • Bortezomib (German)
  • Bortézomib (French)
  • Bortezomib (Spanish)

Generic Names

  • Bortezomib (OS: BAN, USAN, JAN)
  • LDP-341 (IS)
  • MG 341 (IS)
  • MLN-341 (IS)
  • PS-341 (IS)
  • UNII-69G8BD63PP (IS)

Brand Names

  • Borcade
    Koçak, Turkey
  • Bortezomib Accord
    Accord Healthcare, Slovenia
  • Bortezomib Actavis
    Actavis Baltics Eesti, Estonia
  • Bortezomib Adamed
    Adamed, Netherlands; Adamed, Poland
  • Bortezomib B-Medical
    B-Medical, Netherlands
  • Bortezomib Genthon
    Genthon, Netherlands
  • Bortezomib Norameda
    Norameda, Estonia
  • Bortezomib Polpharm
    Polpharma, Netherlands
  • Bortezomib Synthon
    Synthon, Netherlands
  • Bortezomib Teva
    Teva Eesti, Estonia
  • Bortezomib Zentiva
    Zentiva, Netherlands
  • Bortrac
    Glenmark, India
  • Velcade
    Ben Venue, China; Ben Venue, Oman; Haemato Pharm, Austria; Inopha, Austria; Janssen, Australia; Janssen, Brazil; Janssen, Canada; Janssen, Chile; Janssen, Finland; Janssen, Hong Kong; Janssen, Hungary; Janssen, Ireland; Janssen, Iceland; Janssen, Lebanon; Janssen, Malaysia; Janssen, Norway; Janssen, New Zealand; Janssen, Philippines; Janssen, Romania; Janssen, Sweden; Janssen, Singapore; Janssen, Slovakia; Janssen, Thailand; Janssen, South Africa; Janssen Cilag, Argentina; Janssen Cilag, Netherlands; Janssen Cilag, Serbia; Janssen Pharmaceutical, Japan; Janssen-Cilag, Bosnia & Herzegowina; Janssen-Cilag, Belgium; Janssen-Cilag, Switzerland; Janssen-Cilag, Colombia; Janssen-Cilag, Czech Republic; Janssen-Cilag, Germany; Janssen-Cilag, Denmark; Janssen-Cilag, Ecuador; Janssen-Cilag, France; Janssen-Cilag, United Kingdom; Janssen-Cilag, Greece; Janssen-Cilag, Israel; Janssen-Cilag, Lithuania; Janssen-Cilag, Latvia; Janssen-Cilag, Mexico; Janssen-Cilag, Poland; Janssen-Cilag, Vietnam; Janssen-Cilag International, Austria; Johnson & Johnson, Croatia (Hrvatska); Johnson & Johnson, Indonesia; Johnson & Johnson, Turkey; Millennium, United States
    Janssen-Cilag, Portugal
  • Vortemyel
    Alvogen, Estonia; Alvogen, Netherlands
  • Zegomib
    Egis, Netherlands


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.